Notes

Improved Evaluation associated with Bio-Oil Produce Depending on Pyrolysis Conditions as well as Bio-mass End projects Using GA- and also PSO-ANFIS Types.
rther in vivo and toxicological studies are carried out.Purpose To evaluate the efficacy and safety of laparoscopic nerve-sparing radical hysterectomy (LNSRH) in the treatment of early cervical cancer. Methods The clinical data of 152 patients with early cervical cancer undergoing radical hysterectomy (RH) were retrospectively analyzed, and the patients were divided into LNSRH group (n=76) and laparoscopic RH (LRH) group (n=76) according to the surgical approaches. The tumor recurrence and survival were recorded during postoperative follow-up, and the disease-free survival (DFS) and overall survival (OS) were compared between the two groups of patients. Results The general clinical characteristics were comparable between the two groups of patients. LNSRH group had a remarkably longer operation time (p less then 0.001) and a notably shorter length of hospital stay (p less then 0.001) than LRH group. The postoperative in-dwelling time of urinary catheter in LNSRH group was evidently shorter than that in LRH group (p less then 0.001). Besides, the time of first flatus and defecation after operation was markedly shortened in LNSRH group compared with that in LRH group, with statistically significant differences (p less then 0.001). In comparison with those in LRH group, the incidence rate of bladder dysfunction was obviously decreased (p less then 0.001), while the urodynamic indexes at 6 months after operation were prominently better in LNSRH group (p less then 0.05). According to the follow-up results, the 5-year OS was 84.9% and 88% in LNSRH group and LRH group, respectively, and the DFS was 74.0% and 78.7%, respectively. PD166866 Log-rank test showed that the differences in OS and DFS between the two groups of patients were not statistically significant (p=0.275, p=0.213). Conclusions LNSRH is safe and effective in treating early cervical cancer and can result in similar tumor recurrence and long-term survival to LRH. However, it has superior protective effects on the bladder and bowel functions, which is worthy of popularization and application.Purpose Since older age is a risk factor for chemotherapy toxicities, a prediction tool that can accurately identify older patients who are at risk for toxicity is necessary. The Cancer and Aging Research Group (CARG) toxicity tool was developed to predict chemotherapy toxicity risk in older patients. However, whether this tool is predictive of the toxicities for patients with specific tumor types who are receiving specific chemotherapy is unclear. This study evaluated whether the CARG toxicity tool is useful for the clinical practice of the gynecologist in predicting toxicity in older patients with gynecologic cancer treated with platinum and taxane-based chemotherapy. Methods We enrolled 34 patients aged ≥ 65 years with ovarian and endometrial cancer who received platinum and taxane-based chemotherapy into this study. Before starting chemotherapy, each patient was scored using the CARG toxicity tool. The patients were divided into three groups based on the risk of chemotherapy toxicities. We evaluated the associations of each risk group with toxicity incidence, treatment interruption and cycle delay. Results There was a significant difference in the incidence of two or more grade 3 to 5 toxicities among the risk groups (p=0.0479). Treatment interruption caused by toxicity was also significantly different among the risk groups (p=0.001). Conclusions Our study confirmed that the CARG toxicity tool could predict chemotherapy toxicity in older patients with ovarian and endometrial cancer treated with platinum and taxane-based chemotherapy. Our results indicate that this tool is useful for the gynecologist in everyday practice.Purpose This research tried to explore the expression level of II cGMP-dependent protein kinase (PKG2) in human ovarian tissue and to clarify the molecular mechanism of EGFR regulation and its clinical significance. Methods The expression levels of PKG2 and EGFR in 10 normal ovarian tissues, 14 benign ovarian tumor tissues and 39 epithelial ovarian cancer tissues preserved in the archives of the Affiliated Hospital of Xuzhou Medical University from 2016 to 2018 were detected by real-time fluorescence quantitative (RT-PCR), and the correlation between the expressions of the two genes was analyzed. The expressions of in vitro cultured ovarian cancer cell lines SKOV3, PKG2 and EGFR were detected by RT-PCR and western blot, and the over-expressed PKG2 plasmid and PKG2 small interfering RNA (siRNA) were transfected into the cells, and the protein and phosphorylation of Akt and ERK in EGFR and its downstream signaling pathway were detected by western blot. Results Compared with normal ovarian tissue, the mRNA and protein expression levels of PKG2 in ovarian cancer tissue and SKOV3 cell line were significantly reduced (p less then 0.05). However, the mRNA and protein expression levels of EGFR in ovarian cancer tissue and SKOV3 cell line were both high (p less then 0.05). In addition, after transient transfection of PKG2, the expression changes of PKG2 significantly affected the expression of EGFR, and PKG2 over-expression could significantly inhibit the phosphorylation of Akt and ERK in EGFR and its downstream signaling pathways, thereby affecting cell proliferation. Conclusion PKG2 may play a role in inhibiting EGFR expression in ovarian cancer, but the specific mechanism of its effect on tumor development still needs to be further explored.Purpose This study was conducted to assess the anticancer role of gammacerane against human endometrial cancer. Methods The human RL-95 cell line (endometrial cancer) and SV40 (normal endometrial cells) were used in this study. The MTT-based estimation of cell proliferation assay along with the colony formation assay were used for assessing the cell viability. Acridine orange (AO)/Ethidium bromide (EB) staining followed by fluorescent microscopy was performed for estimation of cell apoptosis. Flow cytometry was used to assess the cell cycle phase distribution of cancer cells. Cell migration and invasion were estimated using wound healing and transwell assay, respectively. Western blotting was used for protein expression studies. Results The cell proliferation assay revealed that gammacerane treatment led to loss of viability of RL-95 cancer cells in a concentration-dependent manner. However, the antiproliferative effects were comparatively less prominent when gammacerane was used against the SV40 normal endometrial cells.
My Website: https://www.selleckchem.com/products/pd-166866.html